Popa M, Stefănescu A M, Dumitriu L, Dimitriu V, Bartoc R
C. I. Parhon Institute of Endocrinology, Bucharest, Romania.
Endocrinologie. 1989 Jan-Mar;27(1):35-41.
Urinary excretion of monoamine metabolites (noradrenaline-NA, adrenaline-A, 3-methoxy-4-hydroxyphenyl glycol-MHPG, homovanillic acid-HVA, 5-hydroxyindole acetic acid-5 HIAA) was studied in four groups of children as follows: Group I consisting of obese children subjected to caloric restriction and to a short term course of thyroid extract in "low" dosage (1-2 mg/kg bwt), Group II consisting of obese children subjected to diet alone, Group III consisting of children myxedema and subjected to a short term course of thyroid extract given in the "high" dosage (3-5 mg/kg bwt) and Group IV consisting of GH deficient short children having (many of them) thyrotropin deficiency and subjected to a short term course of thyroid extract in "very high" dosage (5-10 mg/bwt). In obese, calorie-restricted children, the previously low mean level of 5 HIAA excretion was further lowered by thyroid extract. In obese children subjected to calorie restriction alone no urinary abnormality was noted. The congenitally hypothyroid patients had low levels of basal 5 HIAA when compared to controls. The degrees of 5-hydroxy tryptamine (5 HT) deficiency in Group III was similar to the obese groups. The thyroid extract course did not influence, at least in short term administration, the low 5 HIAA levels in group III. In GH deficient, short children (group IV) thyroid extract had no significant effect on urinary pattern of monoamine metabolites. A central 5 HT deficiency may tentatively explain the mood disturbances and possibly the other psychic disorders in both the obese and myxedematous patients. The different effects of thyroid extract on 5 HIAA may also witness the differences in the food intake behaviour in these two conditions.
对四组儿童的单胺代谢产物(去甲肾上腺素 - NA、肾上腺素 - A、3 - 甲氧基 - 4 - 羟基苯乙二醇 - MHPG、高香草酸 - HVA、5 - 羟色胺乙酸 - 5 HIAA)的尿排泄情况进行了如下研究:第一组由接受热量限制并服用低剂量(1 - 2毫克/千克体重)甲状腺提取物短期疗程的肥胖儿童组成;第二组由仅接受饮食控制的肥胖儿童组成;第三组由黏液水肿儿童组成,并接受高剂量(3 - 5毫克/千克体重)甲状腺提取物短期疗程;第四组由生长激素缺乏的矮小儿童组成(其中许多人促甲状腺激素缺乏),并接受极高剂量(5 - 10毫克/体重)甲状腺提取物短期疗程。在肥胖且热量受限的儿童中,甲状腺提取物使先前较低的5 HIAA排泄平均水平进一步降低。在仅接受热量限制的肥胖儿童中,未发现尿液异常。与对照组相比,先天性甲状腺功能减退患者的基础5 HIAA水平较低。第三组中5 - 羟色胺(5 HT)缺乏的程度与肥胖组相似。甲状腺提取物疗程至少在短期给药时,并未影响第三组中较低的5 HIAA水平。在生长激素缺乏的矮小儿童(第四组)中,甲状腺提取物对单胺代谢产物的尿液模式没有显著影响。中枢性5 HT缺乏可能初步解释肥胖和黏液水肿患者的情绪障碍以及可能的其他精神障碍。甲状腺提取物对5 HIAA的不同影响也可能证明这两种情况下食物摄入行为的差异。